Welcome, Guest. Please login or register.
October 23, 2017, 04:20:17 PM

Login with username, password and session length

  • Total Posts: 721137
  • Total Topics: 58503
  • Online Today: 352
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 5
Guests: 297
Total: 302


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Early Antiretroviral Therapy Suggested for HIV/HCV Coinfected Patients  (Read 2168 times)

0 Members and 1 Guest are viewing this topic.

Offline Tim Horn

  • Member
  • Posts: 799

Early Antiretroviral Therapy Suggested for HIV/HCV Coinfected Patients

By Tim Horn, Senior Writer & Editor, AIDSmeds.com

A new study suggests that people living with both HIV and hepatitis C virus (HCV) infection shouldn't wait until their CD4 (T4 cell) counts fall below 300 before starting antiretroviral therapy. The results were published in the December issue of the online medical journal PLoS Medicine by researchers from the Partners AIDS Research Center (PARC) at Massachusetts General Hospital (MGH) in Boston.

Because HIV and HCV have overlapping transmission routes such as contaminated blood products, sharing drug injection needles, and unprotected sex between 25% and 33% of people living with HIV are coinfected with HCV.

Most people who are infected with HCV experience chronic disease, leading to life-threatening liver damage (hepatitis). While it usually takes decades for HCV infection to causes liver failure, people infected with HIV and HCV can experience more rapid disease progression. What's more, as the health of the liver becomes compromised due to HCV infection, antiretroviral therapy can be less effective and tolerable.

Over the years, researchers have found that a sizable minority of people who are infected with HCV manage to control the virus and never get liver disease. Studies involving these people suggest that their immune systems mount a strong immune response to HCV.

Researchers at PARC have been studying similar immune responses in long-term nonprogressors (LTNPs), a small group of HIV-positive people who maintain very low viral loads and higher CD4 cell counts for many years without antiretroviral therapy.

Many of these patients, PARC investigators and other groups suggest, have particularly robust HIV-specific CD4 and "killer" CD8 cell responses that maintain control of HIV replication very early on in the course of infection. Similar CD4 and CD8 cell responses have been shown to play a role in the control of HCV infection.

Building upon this knowledge, the PARC researchers set out to understand how infection with HIV compromises CD4 and CD8 responses to HCV and, ultimately, the control of HCV disease progression.

The PARC research team recruited 94 patients, all of whom were infected with HCV, and divided them into four groups. One group was made up of patients with HIV and HCV coinfection, all of whom had high HCV viral loads. A second group consisted of coinfected patients with undetectable HCV viral loads. The two other groups included patients infected with HCV but not HIV, either with high or undetectable levels of HCV.

The researchers focused on the individuals who, despite coinfection with HIV, were able to control their HCV infection. They found that those individuals managed to maintain relatively high levels of CD4 and CD8 cells that specifically recognize HCV.

However, a quarter of these patients failed to maintain undetectable HCV viral loads over an observation period of 2.5 years. This HCV viral load rebound was associated with a drop in the HCV-specific CD4 cell response. Following HCV viral load rebounds in these patients, HCV did not return to undetectable levels during the study. During the same period, none of the 16 HIV-uninfected people with controlled HCV infection experienced a recurrence of detectable HCV.

Of interest, the researchers discovered a common feature among the coinfected patients who were able to maintain low HCV viral loads. Maintaining higher CD4 cell counts, either through long-term nonprogression of HIV or the use of antiretroviral therapy, was the most important shared characteristic of these individuals. In other words, coinfected patients who did not let their CD4 cell count fall below 300 were more likely keep their HCV infection in check, compared to those who saw their CD4 counts fall below this threshold.

These results, the authors suggest, may have significant implications for people infected with both HIV and HCV. A primary finding of this study is that HCV control is lost in HIV-positive people with depleted CD4 counts, notably counts below 300. In turn, early antiretroviral treatment may be of significant benefit to coinfected patients.

"T-cell responses against HCV are preserved by avoiding CD4+ cell depletion due to progressive HIV infection," the researchers write," indicating a potential immunologic benefit of treatment of HIV in coinfected individuals before the CD4 cell counts fall below 300 cells per microliter, a threshold at the higher end of the current range where initiation of treatment is typically recommend."

"Currently a nationwide trial is recruiting people for a study examining whether earlier treatment of HIV will improve hepatitis C treatment outcomes," says Arthur Kim, MD, of PARC and a lead investigator of the study. "Part of this study will investigate how earlier treatment may affect immune responses. It also will be important to follow the impact of loss of HCV control on liver disease, since this will probably have important consequences for patients with HIV."


Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus HIV coinfection. PLoS Medicine 3(12):e492, 2006.


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.